These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37115550)

  • 1. Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.
    Maeda H; Shingai R; Takeda K; Hara A; Murai Y; Ofuchi M
    JAMA Netw Open; 2023 Apr; 6(4):e238875. PubMed ID: 37115550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies.
    Mooghali M; Wallach JD; Ross JS; Ramachandran R
    JAMA Netw Open; 2024 Aug; 7(8):e2430486. PubMed ID: 39190303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022.
    Mousavi I; Olivier T; Prasad V
    JAMA Netw Open; 2022 Jun; 5(6):e2216058. PubMed ID: 35687338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
    Ranganathan S; Haslam A; Tuia J; Prasad V
    J Cancer Policy; 2024 Mar; 39():100462. PubMed ID: 38061492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency.
    Hatogai K; Kato Y; Hirase C
    Acta Oncol; 2021 Feb; 60(2):143-148. PubMed ID: 33460336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
    Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
    JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
    Hakariya H; Moriarty F; Ozaki A; Mulinari S; Saito H; Tanimoto T
    Clin Transl Sci; 2024 Jul; 17(7):e13879. PubMed ID: 38987923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
    Apolone G; Joppi R; Bertele' V; Garattini S
    Br J Cancer; 2005 Sep; 93(5):504-9. PubMed ID: 16136026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.
    Downing NS; Aminawung JA; Shah ND; Krumholz HM; Ross JS
    JAMA; 2014 Jan 22-29; 311(4):368-77. PubMed ID: 24449315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
    He Q; Li Q; Lv F; Kaitin KI; Shao L
    Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.